Baxter Q2 sales rise 4% to $2.81 billion; adjusted EPS up 28% to $0.59
Baxter reported second-quarter 2025 sales from continuing operations of $2.81 billion, up 4% on a reported basis and 1% on an operational basis, which the company said was in line with its prior guidance. Adjusted diluted EPS from continuing operations rose 28% to $0.59, while U.S. GAAP diluted EPS from continuing operations was $0.24. The company also updated its full-year 2025 adjusted EPS guidance to $2.42 to $2.52.
Key points
- Q2 2025 sales from continuing operations of $2.81 billion, up 4% reported and 1% operational
- Adjusted diluted EPS from continuing operations of $0.59, up 28% from the prior year; GAAP diluted EPS from continuing operations of $0.24
- Full-year 2025 adjusted EPS from continuing operations guidance of $2.42 to $2.52; third-quarter guidance of $0.58 to $0.62
- Andrew Hider's appointment as president and CEO was previously announced July 7, 2025, with a start date by Sept. 3, 2025
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.